PsoriasisPro Featured Presentations
PsoriasisPro is pleased to present this series of discussions featuring national thought leaders in the field of dermatology. These presentations are designed to take a deeper dive into the clinical data supporting the Clobex® (clobetasol propionate) and Vectical® (calcitriol) Ointment line of products.
A Clinical Review of the Differentiation of Calcitriol 3 µg/g Ointment and Calcipotriene 50 µg/g Ointment in Subjects With Mild to Moderate Chronic Plaque Psoriasis
The results of a clinical study of the efficacy and safety of calcitriol 3 µg/g Ointment and calcipotrene 50 µg/g Ointment are discussed, in addition to the importance of topical Vitamin D3 therapy as a component of psoriasis care.
Clinical Review of Efficacy and Long-term Safety Data of Vectical® (calcitriol) Ointment 3 µg/g
The long-term efficacy and safety of Vectical® Ointment are reviewed, featuring Week 26 and Week 52 results.
Use of Topical Vitamin D Therapy for Psoriasis: 52 Week Long Term Safety Data
Leon Kircik, MD, interviews national thought leader Mark Lebwohl, MD, about the long-term results of a published clinical study of calcitriol 3 μg/g ointment in the treatment of moderate to severe plaque psoriasis.
Clobex® (clobetasol propionate) Shampoo, 0.05%
A discussion of the use of Clobex® Shampoo for the treatment of moderate to severe scalp psoriasis in adult patients.
Clobex® (clobetasol propionate) Lotion, 0.05%
A review of the data available for Clobex® Lotion for the treatment of moderate to severe corticosteroid responsive dermatoses.
